On March 3rd and 4th, BioPharma Ambition drew some 400 delegates to Dublin to explore the themes defining biopharmaceutical innovation right across the medicines lifecycle. The event was held just as COVID-19, later a global pandemic, began to dominate the news agenda and prompt policymakers to consider their response. The event was held before restrictions were announced. The disease, on which biopharmaceutical innovators globally are working to find vaccines and treatments, was the backdrop to BioPharma Ambition 2020. It brought into sharp focus the purpose of medicines innovation - our shared journey in discovering, developing and making available quickly the best medicines to stop sometimes deadly diseases.
BioPharma Ambition 2020 was the third time the Irish Pharmaceutical Healthcare Association (IPHA), BioPharmaChem Ireland (BPCI) and the National Institute for Bioprocessing Research and Training (NIBRT) came together to create a thought-leadership platform for biopharmaceutical innovation. The aim was to position Ireland at the nexus of globally networked innovation. It was a whole-of-industry event, drawing on experts’ perspectives to share an exciting story of medicines discovery, development, manufacture and adoption.